Review



dermal microvascular endothelial cells hdmecs  (Procell Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Procell Inc dermal microvascular endothelial cells hdmecs
    Dermal Microvascular Endothelial Cells Hdmecs, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dermal microvascular endothelial cells hdmecs/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    dermal microvascular endothelial cells hdmecs - by Bioz Stars, 2025-02
    86/100 stars

    Images



    Similar Products

    96
    PromoCell human dermal microvascular endothelial cells hdmec
    Human Dermal Microvascular Endothelial Cells Hdmec, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dermal microvascular endothelial cells hdmec/product/PromoCell
    Average 96 stars, based on 1 article reviews
    human dermal microvascular endothelial cells hdmec - by Bioz Stars, 2025-02
    96/100 stars
      Buy from Supplier

    86
    PromoCell human dermal microvascular endothelial cells hdmecs
    Clioquinol selectively targets ECs and inhibits angiogenesis. a Viability (% of 0 µM) of HUVECs, <t>HDMECs,</t> hPC-PLs, NHDFs, MDA-MB-231, MCF-7, and 4T1-Luc2 cells after 48-hour exposure to a serial dilution of clioquinol, as assessed by WST-1 assay ( n = 4). b Cytotoxicity (% of total cell death) of clioquinol against HUVECs after 24-hour treatment, as assessed by LDH assay ( n = 4). c Proliferation (% of 0 µM) of HUVECs treated with 0, 2.5, 5, or 10 µM clioquinol for 24 h, as assessed by BrdU incorporation assay ( n = 4). d Light microscopic images of migrated HUVECs after 5-hour incubation. The cells were treated with 0, 2.5, 5, or 10 µM clioquinol for 24 h prior to this assay. Scale bar: 65 μm. e Migration (% of 0 µM) of HUVECs treated as described in (d) ( n = 3). f Phase-contrast microscopic images of tube-forming HUVECs after 18-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. Scale bar: 700 μm. g Tube formation (% of 0 µM) of HUVECs treated as described in (f) ( n = 3). h Phase-contrast microscopic images of HUVEC spheroids after 24-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. Scale bar: 95 μm. i Sprouting (% of 0 µM) of HUVEC spheroids treated as described in (h) ( n = 11–13). j Fluorescence microscopic images of Matrigel plugs containing DMSO (control) or 10 µM clioquinol. The sections were stained with an anti-CD31 antibody (red) and Hoechst 33342 (blue) for the visualization of ECs and cell nuclei, respectively. Scale bar: 45 μm. k Microvessel density (% of control) of control and clioquinol-containing Matrigel plugs, as assessed by immunohistochemistry ( n = 7). Means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant. (a-c, e, g, i: one-way ANOVA with Tukey’s multiple comparisons test; k: unpaired Student’s t-test)
    Human Dermal Microvascular Endothelial Cells Hdmecs, supplied by PromoCell, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dermal microvascular endothelial cells hdmecs/product/PromoCell
    Average 86 stars, based on 1 article reviews
    human dermal microvascular endothelial cells hdmecs - by Bioz Stars, 2025-02
    86/100 stars
      Buy from Supplier

    86
    Lonza human dermal microvascular endothelial cells hdmecs
    HA affects tumor cell proliferation and the CTCL microenvironment. ( A ) Proliferation of EL4 and HuT78 cells in vitro in the presence of LMWHA and HMWHA. The left graph shows the number of live EL4 and HuT78 cells (n = 4 each). The right panel shows the results of MTT proliferation assays (n = 6 each). The MTT results refer to cells measured five days after treatment. Asterisks indicate p < 0.05 in comparing LMWHA and HMWHA. ( B ) Change in tumor volume under LMWHA stimulation in vivo. The asterisk indicates p < 0.05. Representative images of tumor size at day 10 are shown. ( C ) Expression of Th1 and Th2 chemokines by M2 macrophages with HA stimulation (n = 4 each). ( D ) Tube formation assay performed with <t>HDMECs</t> treated with LMWHA or HMWHA. Representative images are shown (n = 5 each). Bar = 300 µm. AU, arbitrary unit; NT, no treatment; LMW, low-molecular-weight; HMW, high-molecular-weight.
    Human Dermal Microvascular Endothelial Cells Hdmecs, supplied by Lonza, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dermal microvascular endothelial cells hdmecs/product/Lonza
    Average 86 stars, based on 1 article reviews
    human dermal microvascular endothelial cells hdmecs - by Bioz Stars, 2025-02
    86/100 stars
      Buy from Supplier

    86
    Procell Inc dermal microvascular endothelial cells hdmecs
    HA affects tumor cell proliferation and the CTCL microenvironment. ( A ) Proliferation of EL4 and HuT78 cells in vitro in the presence of LMWHA and HMWHA. The left graph shows the number of live EL4 and HuT78 cells (n = 4 each). The right panel shows the results of MTT proliferation assays (n = 6 each). The MTT results refer to cells measured five days after treatment. Asterisks indicate p < 0.05 in comparing LMWHA and HMWHA. ( B ) Change in tumor volume under LMWHA stimulation in vivo. The asterisk indicates p < 0.05. Representative images of tumor size at day 10 are shown. ( C ) Expression of Th1 and Th2 chemokines by M2 macrophages with HA stimulation (n = 4 each). ( D ) Tube formation assay performed with <t>HDMECs</t> treated with LMWHA or HMWHA. Representative images are shown (n = 5 each). Bar = 300 µm. AU, arbitrary unit; NT, no treatment; LMW, low-molecular-weight; HMW, high-molecular-weight.
    Dermal Microvascular Endothelial Cells Hdmecs, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dermal microvascular endothelial cells hdmecs/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    dermal microvascular endothelial cells hdmecs - by Bioz Stars, 2025-02
    86/100 stars
      Buy from Supplier

    86
    ScienCell human dermal microvascular endothelial cells hdmecs
    HA affects tumor cell proliferation and the CTCL microenvironment. ( A ) Proliferation of EL4 and HuT78 cells in vitro in the presence of LMWHA and HMWHA. The left graph shows the number of live EL4 and HuT78 cells (n = 4 each). The right panel shows the results of MTT proliferation assays (n = 6 each). The MTT results refer to cells measured five days after treatment. Asterisks indicate p < 0.05 in comparing LMWHA and HMWHA. ( B ) Change in tumor volume under LMWHA stimulation in vivo. The asterisk indicates p < 0.05. Representative images of tumor size at day 10 are shown. ( C ) Expression of Th1 and Th2 chemokines by M2 macrophages with HA stimulation (n = 4 each). ( D ) Tube formation assay performed with <t>HDMECs</t> treated with LMWHA or HMWHA. Representative images are shown (n = 5 each). Bar = 300 µm. AU, arbitrary unit; NT, no treatment; LMW, low-molecular-weight; HMW, high-molecular-weight.
    Human Dermal Microvascular Endothelial Cells Hdmecs, supplied by ScienCell, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dermal microvascular endothelial cells hdmecs/product/ScienCell
    Average 86 stars, based on 1 article reviews
    human dermal microvascular endothelial cells hdmecs - by Bioz Stars, 2025-02
    86/100 stars
      Buy from Supplier

    96
    PromoCell hdmec
    HA affects tumor cell proliferation and the CTCL microenvironment. ( A ) Proliferation of EL4 and HuT78 cells in vitro in the presence of LMWHA and HMWHA. The left graph shows the number of live EL4 and HuT78 cells (n = 4 each). The right panel shows the results of MTT proliferation assays (n = 6 each). The MTT results refer to cells measured five days after treatment. Asterisks indicate p < 0.05 in comparing LMWHA and HMWHA. ( B ) Change in tumor volume under LMWHA stimulation in vivo. The asterisk indicates p < 0.05. Representative images of tumor size at day 10 are shown. ( C ) Expression of Th1 and Th2 chemokines by M2 macrophages with HA stimulation (n = 4 each). ( D ) Tube formation assay performed with <t>HDMECs</t> treated with LMWHA or HMWHA. Representative images are shown (n = 5 each). Bar = 300 µm. AU, arbitrary unit; NT, no treatment; LMW, low-molecular-weight; HMW, high-molecular-weight.
    Hdmec, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hdmec/product/PromoCell
    Average 96 stars, based on 1 article reviews
    hdmec - by Bioz Stars, 2025-02
    96/100 stars
      Buy from Supplier

    Image Search Results


    Clioquinol selectively targets ECs and inhibits angiogenesis. a Viability (% of 0 µM) of HUVECs, HDMECs, hPC-PLs, NHDFs, MDA-MB-231, MCF-7, and 4T1-Luc2 cells after 48-hour exposure to a serial dilution of clioquinol, as assessed by WST-1 assay ( n = 4). b Cytotoxicity (% of total cell death) of clioquinol against HUVECs after 24-hour treatment, as assessed by LDH assay ( n = 4). c Proliferation (% of 0 µM) of HUVECs treated with 0, 2.5, 5, or 10 µM clioquinol for 24 h, as assessed by BrdU incorporation assay ( n = 4). d Light microscopic images of migrated HUVECs after 5-hour incubation. The cells were treated with 0, 2.5, 5, or 10 µM clioquinol for 24 h prior to this assay. Scale bar: 65 μm. e Migration (% of 0 µM) of HUVECs treated as described in (d) ( n = 3). f Phase-contrast microscopic images of tube-forming HUVECs after 18-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. Scale bar: 700 μm. g Tube formation (% of 0 µM) of HUVECs treated as described in (f) ( n = 3). h Phase-contrast microscopic images of HUVEC spheroids after 24-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. Scale bar: 95 μm. i Sprouting (% of 0 µM) of HUVEC spheroids treated as described in (h) ( n = 11–13). j Fluorescence microscopic images of Matrigel plugs containing DMSO (control) or 10 µM clioquinol. The sections were stained with an anti-CD31 antibody (red) and Hoechst 33342 (blue) for the visualization of ECs and cell nuclei, respectively. Scale bar: 45 μm. k Microvessel density (% of control) of control and clioquinol-containing Matrigel plugs, as assessed by immunohistochemistry ( n = 7). Means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant. (a-c, e, g, i: one-way ANOVA with Tukey’s multiple comparisons test; k: unpaired Student’s t-test)

    Journal: Angiogenesis

    Article Title: Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization

    doi: 10.1007/s10456-024-09965-1

    Figure Lengend Snippet: Clioquinol selectively targets ECs and inhibits angiogenesis. a Viability (% of 0 µM) of HUVECs, HDMECs, hPC-PLs, NHDFs, MDA-MB-231, MCF-7, and 4T1-Luc2 cells after 48-hour exposure to a serial dilution of clioquinol, as assessed by WST-1 assay ( n = 4). b Cytotoxicity (% of total cell death) of clioquinol against HUVECs after 24-hour treatment, as assessed by LDH assay ( n = 4). c Proliferation (% of 0 µM) of HUVECs treated with 0, 2.5, 5, or 10 µM clioquinol for 24 h, as assessed by BrdU incorporation assay ( n = 4). d Light microscopic images of migrated HUVECs after 5-hour incubation. The cells were treated with 0, 2.5, 5, or 10 µM clioquinol for 24 h prior to this assay. Scale bar: 65 μm. e Migration (% of 0 µM) of HUVECs treated as described in (d) ( n = 3). f Phase-contrast microscopic images of tube-forming HUVECs after 18-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. Scale bar: 700 μm. g Tube formation (% of 0 µM) of HUVECs treated as described in (f) ( n = 3). h Phase-contrast microscopic images of HUVEC spheroids after 24-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. Scale bar: 95 μm. i Sprouting (% of 0 µM) of HUVEC spheroids treated as described in (h) ( n = 11–13). j Fluorescence microscopic images of Matrigel plugs containing DMSO (control) or 10 µM clioquinol. The sections were stained with an anti-CD31 antibody (red) and Hoechst 33342 (blue) for the visualization of ECs and cell nuclei, respectively. Scale bar: 45 μm. k Microvessel density (% of control) of control and clioquinol-containing Matrigel plugs, as assessed by immunohistochemistry ( n = 7). Means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant. (a-c, e, g, i: one-way ANOVA with Tukey’s multiple comparisons test; k: unpaired Student’s t-test)

    Article Snippet: Human umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells (HDMECs), and human pericytes from placenta (hPC-PLs) were purchased from PromoCell (Heidelberg, Germany).

    Techniques: Serial Dilution, WST-1 Assay, Lactate Dehydrogenase Assay, BrdU Incorporation Assay, Incubation, Migration, Fluorescence, Control, Staining, Immunohistochemistry

    Clioquinol selectively down-regulates VEGFR2 in ECs. a Western blots showing VEGFR2, VEGFR1, Tie2, FGFR1, and β-actin expression in HUVECs after 4-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. b - e Expression level (% of 0 µM) of VEGFR2 ( b ), VEGFR1 ( c ), Tie2 ( d ), and FGFR1 ( e ) normalized to β-actin in HUVECs treated as described in (a) ( n = 3 independent experiments). f Mean fluorescence intensity (MFI) of membrane VEGFR2 on HUVECs treated with or without 10 µM clioquinol for 0.5, 1, 2, 3, and 4 h, as assessed by flow cytometry ( n = 4). g Phase-contrast microscopic images of HUVEC spheroids after 24-hour treatment without or with clioquinol in the absence or presence of 25 ng/mL VEGF. Scale bar: 135 μm. h Sprouting (% of control) of HUVEC spheroids treated as described in (g) ( n = 13–15). i Western blots showing VEGFR2 and β-actin expression in HUVECs, HDMECs, hPC-PLs, NHDFs, MCF-7, MDA-MB-231, and 4T1-Luc2 cells. j Expression level (% of HUVEC) of VEGFR2 normalized to β-actin in different cell types as described in (i) ( n = 3 independent experiments). k Correlation between cell viability and VEGFR2 expression following exposure to 10 or 25 µM clioquinol. Means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant. (b-e, h, j: one-way ANOVA with Tukey’s multiple comparisons test; f: unpaired Student’s t-test; k: Pearson correlation coefficient)

    Journal: Angiogenesis

    Article Title: Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization

    doi: 10.1007/s10456-024-09965-1

    Figure Lengend Snippet: Clioquinol selectively down-regulates VEGFR2 in ECs. a Western blots showing VEGFR2, VEGFR1, Tie2, FGFR1, and β-actin expression in HUVECs after 4-hour treatment with 0, 2.5, 5, or 10 µM clioquinol. b - e Expression level (% of 0 µM) of VEGFR2 ( b ), VEGFR1 ( c ), Tie2 ( d ), and FGFR1 ( e ) normalized to β-actin in HUVECs treated as described in (a) ( n = 3 independent experiments). f Mean fluorescence intensity (MFI) of membrane VEGFR2 on HUVECs treated with or without 10 µM clioquinol for 0.5, 1, 2, 3, and 4 h, as assessed by flow cytometry ( n = 4). g Phase-contrast microscopic images of HUVEC spheroids after 24-hour treatment without or with clioquinol in the absence or presence of 25 ng/mL VEGF. Scale bar: 135 μm. h Sprouting (% of control) of HUVEC spheroids treated as described in (g) ( n = 13–15). i Western blots showing VEGFR2 and β-actin expression in HUVECs, HDMECs, hPC-PLs, NHDFs, MCF-7, MDA-MB-231, and 4T1-Luc2 cells. j Expression level (% of HUVEC) of VEGFR2 normalized to β-actin in different cell types as described in (i) ( n = 3 independent experiments). k Correlation between cell viability and VEGFR2 expression following exposure to 10 or 25 µM clioquinol. Means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant. (b-e, h, j: one-way ANOVA with Tukey’s multiple comparisons test; f: unpaired Student’s t-test; k: Pearson correlation coefficient)

    Article Snippet: Human umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells (HDMECs), and human pericytes from placenta (hPC-PLs) were purchased from PromoCell (Heidelberg, Germany).

    Techniques: Western Blot, Expressing, Fluorescence, Membrane, Flow Cytometry, Control

    HA affects tumor cell proliferation and the CTCL microenvironment. ( A ) Proliferation of EL4 and HuT78 cells in vitro in the presence of LMWHA and HMWHA. The left graph shows the number of live EL4 and HuT78 cells (n = 4 each). The right panel shows the results of MTT proliferation assays (n = 6 each). The MTT results refer to cells measured five days after treatment. Asterisks indicate p < 0.05 in comparing LMWHA and HMWHA. ( B ) Change in tumor volume under LMWHA stimulation in vivo. The asterisk indicates p < 0.05. Representative images of tumor size at day 10 are shown. ( C ) Expression of Th1 and Th2 chemokines by M2 macrophages with HA stimulation (n = 4 each). ( D ) Tube formation assay performed with HDMECs treated with LMWHA or HMWHA. Representative images are shown (n = 5 each). Bar = 300 µm. AU, arbitrary unit; NT, no treatment; LMW, low-molecular-weight; HMW, high-molecular-weight.

    Journal: Cancers

    Article Title: Impact of Hyaluronic Acid on the Cutaneous T-Cell Lymphoma Microenvironment: A Novel Anti-Tumor Mechanism of Bexarotene

    doi: 10.3390/cancers17020324

    Figure Lengend Snippet: HA affects tumor cell proliferation and the CTCL microenvironment. ( A ) Proliferation of EL4 and HuT78 cells in vitro in the presence of LMWHA and HMWHA. The left graph shows the number of live EL4 and HuT78 cells (n = 4 each). The right panel shows the results of MTT proliferation assays (n = 6 each). The MTT results refer to cells measured five days after treatment. Asterisks indicate p < 0.05 in comparing LMWHA and HMWHA. ( B ) Change in tumor volume under LMWHA stimulation in vivo. The asterisk indicates p < 0.05. Representative images of tumor size at day 10 are shown. ( C ) Expression of Th1 and Th2 chemokines by M2 macrophages with HA stimulation (n = 4 each). ( D ) Tube formation assay performed with HDMECs treated with LMWHA or HMWHA. Representative images are shown (n = 5 each). Bar = 300 µm. AU, arbitrary unit; NT, no treatment; LMW, low-molecular-weight; HMW, high-molecular-weight.

    Article Snippet: Human dermal microvascular endothelial cells (HDMECs) (Lonza, Zulich, Switzerland) were cultured to near confluence and serum-starved overnight.

    Techniques: In Vitro, In Vivo, Expressing, Tube Formation Assay, Molecular Weight